Race Oncology Ltd has released a press release.
Compelling Zantrene Preclinical Kidney Cancer Data
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Oncology: Application for quotation of securities - RAC
- MD Anderson Preclinical AML Study on Zantrene Published
- Race raises $29.7 million in oversubscribed SPP
- Expanded Heart Protection Discovery for Zantrene
- Race Oncology: Notification regarding unquoted securities - RAC
Later from Racura Oncology
- Race Oncology: ASX Small and Mid-Cap Conference Presentation
- Zantrene highly effective in EMD AML Mouse Model
- Supply Agreement for EMD AML Trial
- Race receives Human Ethics AML Trial Approval
- Race Receives Governance Approval for AML EMD & MDS Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology